Diclofenac - LTT Bio-Pharma

Drug Profile

Diclofenac - LTT Bio-Pharma

Alternative Names: Diclofenac sodium eye-drops - LTT Bio-Pharma; LT 0303

Latest Information Update: 05 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator LTT Bio-Pharma
  • Class Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Dry eyes

Most Recent Events

  • 01 Dec 2016 LTT Bio-Pharma completes a phase II trial in Dry eyes in Japan (Ophthalmic) (UMIN000021601)
  • 13 Mar 2016 Phase-II clinical trials in Dry eyes in Japan (Ophthalmic)
  • 12 Aug 2015 Preclinical trials in Dry eyes in Japan before August 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top